The BCG Vaccine for COVID-19: First Verdict and Future Directions

Maria Gonzalez-Perez¹, Rodrigo Sanchez-Tarjuelo², Boris Shor³, Estanislao Nistal-Villan⁴,⁵ and Jordi Ochando¹,²*

¹ Transplant Immunology Unit, Department of Immunology, National Center of Microbiology, Instituto De Salud Carlos III, Madrid, Spain, ² Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States, ³ Manhattan BioSolutions, New York, NY, United States, ⁴ Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-Centro de Estudios Universitarios (CEU), Madrid, Spain, ⁵ Facultad de Medicina, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, Madrid, Spain

Despite of the rapid development of the vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses and the proper infrastructure to vaccinate a good proportion of the world population. In this interim, the accessibility to the Bacille Calmette-Guerin (BCG) may mitigate the pandemic impact in some countries and the BCG vaccine offers significant advantages and flexibility in the way clinical vaccines are administered. BCG vaccination is a highly cost-effective intervention against tuberculosis (TB) and many low-and lower-middle-income countries would likely have the infrastructure, and health care personnel sufficiently familiar with the conventional TB vaccine to mount full-scale efforts to administer novel BCG-based vaccine for COVID-19. This suggests the potential for BCG to overcome future barriers to vaccine roll-out in the countries where health systems are fragile and where the effects of this new coronavirus could be catastrophic. Many studies have reported cross-protective effects of the BCG vaccine toward non-tuberculosis related diseases. Mechanistically, this cross-protective effect of the BCG vaccine can be explained, in part, by trained immunity, a recently discovered program of innate immune memory, which is characterized by non-permanent epigenetic reprogramming of macrophages that leads to increased inflammatory cytokine production and consequently potent immune responses. In this review, we summarize recent work highlighting the potential use of BCG for the treatment respiratory infectious diseases and ongoing SARS-CoV-2 clinical trials. In situations where no other specific prophylactic tools are available, the BCG vaccine could be used as a potential adjuvant, to decrease sickness of SARS-CoV-2 infection and/or to mitigate the effects of concurrent respiratory infections.

**Keywords:** Bacille Calmette-Guerin, SARS-CoV-2, vaccination, trained immunity, cross-protection

INTRODUCTION

Tuberculosis (TB) is a respiratory disease caused by *Mycobacterium tuberculosis* complex (1), a group of bacteria which primarily attacks the lungs along with other body parts such as the kidneys, spine, and brain. This airborne infectious disease can spread from person to person and it was the leading cause of death in the 1900’s in Europe. Following 20 years
of research the TB vaccine was developed by Albert Calmette and Camille Guérin, from whose initials takes its name (BCG, Bacillus Calmette-Guerin). Obtaining the vaccine was not an easy procedure. Calmette and Guérin cultivated *Mycobacterium bovis*, one of the possible tubercle bacilli on a glycerin and potato culture medium and subsequently added ox bile to obtain a more homogeneous suspension, which ended up lowering the virulence of the bacterium. The result was an attenuated strain of the bacteria that could be used as a vaccine. They decided to carry out several animal trials (guinea pigs, rabbits, or horses) until in 1921 they first administered BCG to humans at the Charité Hospital, Paris. From that on, 114,000 infants were orally vaccinated without serious complications until 1928 and the BCG vaccination was proved to be safe (2).

It was soon after its administration that it was observed the beneficial effects of BCG vaccination, with multiple studies reporting non-specific cross-protection of the vaccine against other infectious diseases. Carl Näslund introduced the BCG as a prevention of TB in northern Sweden and informed in 1932 that the vaccine was reducing child mortality unrelated to the TB disease, suggesting that “one could evidently be tempted to find an explanation for this lower mortality among vaccinated children in the idea that BCG provokes a non-specific immunity” (3). However, these protective effects were not studied in detail until nearly 70 years after, when Peter Aaby et al. first reported a 45% mortality reduction due to non-specific beneficial effects of BCG vaccination in West Africa. These pioneer studies described that BCG vaccination was associated with lower incidence of neonatal sepsis and respiratory tract infections that reduced child mortality (4, 5). Further, Peter Aaby et al. reported 60% less acute lower respiratory tract infection (ALRI) in girls below 5 years of age, confirming a non-targeted beneficial effect of BCG vaccination on childhood survival (6). Other examples of BCG vaccination mediated non-specific effects include 70% reduction in pneumonia in Japan (7); 80% decrease in acute upper respiratory tract infection (AURTI), including rhino-pharyngo-laryngo-tracheitis, in the elderly (60–75 years old) in Indonesia (8); and 73% lower rate in upper respiratory tract infections in a phase 2 trial conducted in South Africa (CT02075203) (9). More recently, it has been established that BCG vaccination protects against a variety of viral infections such as influenza virus, yellow fever virus, herpes simplex viruses, respiratory syncytial virus, and human papilloma virus (10).

Since January 2020, a pandemic situation has emerged worldwide as a result of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak. The virus infects the respiratory tract and replicates in cells expressing the ACE2 receptor that are present in the lung parenchyma pneumocytes, the goblet cells along the nasal mucosa and in absorptive enterocytes in the small intestine (11). Scientists around the world are continuously working to develop specific vaccines to lower the incidence of COVID-19 in the population. As there is an urgent need to mitigate the effects of COVID-19, governmental and non-governmental agencies, including the World Health Organization (WHO), urged to test approved therapies that may be used to reduce the consequences of SARS-CoV-2 infection, such as drugs developed for AIDS, Ebola, or Malaria, excluding BCG vaccination, as there was no evidence that the BCG vaccine protected people against infection (12). As of February 2021, several vaccines have been approved for therapeutic use. These include two messenger RNA-based vaccines (Pfizer-Biotech and Moderna) and one adenovirus-based attenuated vaccine (Oxford-AstraZeneca). The three RNA vaccines have been approved by the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (13, 14) and are being currently administered to millions of people. In addition, the Russian vaccine Sputnik has been licensed in Russia, Belarus, Hungary, Serbia, United Arab Emirates and Argentina, and more than 50 countries in Latin America Europe, Africa, and Asia have purchased the vaccine, while the Chinese vaccines CoronaVac (15) and Sinopharm have been approved for emergency used in China and in the United Arab Emirates, respectively.

In principle, the arrival of SARS-CoV-2 specific vaccines and initial clinical trial results concluding that BCG does not reduce COVID-19 mortality overrides the need to further evaluate the effects of BCG vaccination on SARS-CoV-2 infection. However, the BCG vaccine may represent a therapeutic approach to (i) increase the efficacy of current and future SARS-CoV-2 specific vaccines that aim at developing immunological memory, while (ii) mitigate the effects of potential concurrent infections. BCG vaccination offers certain level of protection against different respiratory viral, bacterial and fungal infections that may coexist with SARS-CoV-2 (16) and therefore, coadministration of BCG and SARS-CoV-2 vaccines may have synergistic protective effects, including increased efficacy and/or duration of the memory response. In addition, since BCG vaccination might be associated with a decrease in the incidence of sickness during the COVID-19 pandemic (17), it may help to reduce hospitalizations due to SARS-CoV-2 and other respiratory infections. Here, we review some recent data that addresses the potential use of BCG to diminish the magnitude of COVID-19 and other acute respiratory diseases.

**BCG, TRAINED IMMUNITY AND CROSSPROTECTION**

The ancient innate immune system has evolved to employ multiple defense mechanisms to eliminate infection. In contrast to the adaptive immunity, which relies on the antigen-specificity, additional innate immune cell populations may exhibit heterologous memory responses triggered upon microbial exposure. Indeed, several studies demonstrated that macrophages and natural killer (NK) cells, which have experienced previous pathogen encounter, can be “trained” via epigenetic remodeling to respond to unrelated pathogens (18, 19). Epigenetic marks including as H3K4me1, H3K4me3, and H3K27ac, mediate epigenetic reprogramming of monocytes which results in the opening of chromatin sites at the promoters of pro-inflammatory cytokines such as IL-6, IL-1β, and TNFα (20) (Figure 1). It is plausible that a cross-talk between macrophages and NK cells facilitates the fine-tuning of innate immune program during the
life-time exposure to microbial insults. In support of this notion, vaccination of healthy volunteers with BCG primes macrophages and NK cells, leading to increased cytokine production after *ex vivo* restimulation (3, 21).

A recent study from Netea et al. demonstrated that the BCG vaccine offers a certain degree of cross-protection against a viral infections through trained immunity related mechanisms. Specifically, the study demonstrated the effects of...
BCG vaccination on genome-wide histone modifications induced in trained monocytes, which are associated with reduced levels of yellow fever virus (YFV) viremia due to increased IL-1β production and release (22). This cross-protection effects of BCG against YFV infection confirms the non-specific effects of BCG vaccine described for various viral infections, such as influenza A (H1N1), herpes virus (HSV), respiratory syncytial virus (RSV), and the human papilloma virus (HPV) (10). Since BCG offers protection to TB unrelated viral infections, it was hypothesized that BCG vaccination could also offer protection against SARS-CoV-2 infection in some individuals that have initial defective antiviral responses (23). To explain this, there is another type of immunological mechanism by which BCG could be inducing cross-protection named heterologous immunity. The term heterologous immunity refers to the immunity that can develop to one pathogen after an individual has been exposed to a non-identical pathogen. In this respect, a recent study addressing the homology between SARS-CoV-2 envelope protein and different Mycobacterium strains, presents one sequence of 12 amino acids of SARS-CoV-2 envelope protein has high homology to LytR C-terminal domain-containing proteins of Mycobacterium sp. (24). BLAST analysis is accompanied by detection of Mycobacteria in formalin and paraffin embedded tissue using immune-based microscopic assays showing a coincidental signal using acid-fast bacillus (AFB) staining and a SARS-CoV-2 envelope-specific antibody. In this manuscript, it is proposed that homology may activate heterologous immunity and a Th1/Th17 response, as previously described between adenovirus vaccine vectors and hepatitis C virus (HCV). Therefore, a combination of trained immunity and heterologous immunity by some BCG epitopes could provide immunity through T-cell cross-reactivity that could be responsible for the beneficial clinical effects of BCG.

**BCG STRAINS**

In addition to trial design, the heterogeneity of BCG strains may also influence safety and effectiveness of vaccines against respiratory infections. Today, over 14 sub-strains of BCG have evolved and have been used as BCG vaccine in different laboratories around the world (Figure 2). It was suggested that the strain variation may contribute to the highly variable protective efficacy of BCG against TB observed in clinical trials. The comparative genomic analysis studies and more recently conducted transcriptional and proteomics profiling experiments have produced a comprehensive map of single nucleotide polymorphisms (SNPs), deletions, insertions, and duplications of genomic regions across 14 BCG strains (25, 26). Intriguingly, BCG strains of the duplication group DU2-IV (BCG Phipps, Frappier, Pasteur, and Tice) exhibited the highest levels of virulence in the mouse infection model, whereas BCG strains of the DU2 group II (BCG Sweden and Birkhaug) were among the least virulent group. The more virulent strains were also more effective in protection against *Mycobacterium tuberculosis* challenge (27). At molecular level, BCG-Japan, -Moreau, and -Glaxo strains are naturally defective in the production of phthiocerol dimycocerosates (PDIMs) and phenolic glycolipids (PGLs), two lipid virulence factors, which could compromise their effectiveness during vaccination (28). To compensate for a potential “over-attenuation,” according to the WHO report, a dose of BCG-Japan contains 5-fold more CFU than other distributed BCG vaccines (29). Therefore, selection of the BCG strain, vaccine formulation and route of the administration may ultimately impact the effectiveness of these vaccines against COVID-19 in clinical trials (30).

**BCG AND COVID-19**

Multiple studies are being carried out around the world in an effort to associate the beneficial effects of BCG vaccination on COVID-19. Initial ecological studies established that in countries with BCG vaccination programs have less COVID-19 cases and deaths per population (31, 32), suggesting that trained immunity inducing vaccines may provide protection to bridge the gap before a COVID-19-specific vaccine is developed (33). On the contrary, other studies concluded that BCG vaccination in childhood does not have a protective effect against COVID-19 in adulthood (34). It is possible that due to the different testing and notification approaches, case and deaths incidences of COVID-19 might not differ in a country with BCG vaccination as it is critical to include different variables of interest such as age structure, income, rurality, and population density. A National Institutes of Health (NIH) study attempted to correct potential confounding variables among countries, such as access to health, education, and stage and size of the COVID-19 epidemic, which observed a strong correlation between BCG vaccination policy and reduction of morbidity and mortality due to COVID-19 in different European countries (10% of the augmentation in the BCG index was associated with a 10.4% mortality reduction from COVID-19) (35). Similar conclusions were reached comparing the same geographical area with similar socioeconomic conditions between Spain and Portugal, with different high mortality rates have been observed in Spain where TB vaccination is no longer part of the official vaccination calendar (36). However, it is important to highlight the importance of including new variants to verify the potential of BCG as a vaccine against COVID-19, such as BCG index (proportion of population of a country vaccinated against BCG), HDI score (number of days since one case per million), population density per Km², population >65 years of age, CPI (Corruption Perception Index, government transparency) and percentage of population living in urban areas.

Only ongoing randomized controlled trials (RCTs) will provide answers to whether BCG reduces the incidence and severity of COVID-19 through its cross-protective effects. The phase III randomized clinical trial ACTIVATE (NCT03296423) confirmed that recent vaccination with BCG in elderly (>65 years) protects against new infections. In this trial in which 198 elderly people participated, it was demonstrated the difference between the incidence of new infections after placebo vaccination (42.3%) and BCG vaccination (25.0%), being most of the protection against respiratory tract infections. Furthermore, vaccinated individuals took longer to get infected (16 weeks) than...
the ones vaccinated with placebo (11 weeks). Further statistical analysis indicated a 79% decreased on the risk of acquiring at least one new respiratory infection in a 12 months period for BCG vaccinated group. These benefits were suggested to be mediated by pro-inflammatory cytokines, such as IL-10 TNFα and IL-1β, and therefore associated with the induction of trained immunity. Supporting this view, all BCG vaccinated patients showed an increased proinflammatory pattern after a second stimulation of peripheral blood mononuclear cells (PBMCs) with heat-killed C. albicans or LPS, although insufficient data was obtained in order to correlate the effect (16). The study concluded that BCG vaccination is safe, as recently reported by the same group (17), and can protect the elderly against infections. The study also suggests that BCG vaccination may be able to protect health workers or vulnerable individuals against SARS-CoV-2 virus infection, although larger and specific studies are needed to assess BCG protection against COVID-19.

Whereas most of the randomized clinical trials are set out to investigate the efficacy in COVID-19 prevention, a BATTLE trial in Brazil (NCT04369794) is designed to test BCG in a therapeutic vaccination setting. Specifically, BATLE trial enrolls patients with confirmed COVID-19 symptoms. This prospective, randomized, double-blind study is testing the potential of BCG to affect (a) clinical evolution of COVID-19, (b) elimination of SARS-CoV-2 at different times and disease phenotypes, and (c) seroconversion rate and titration (anti-SARS-CoV-2 IgA, IgM, and IgG). Such therapeutic vaccination strategy addresses the hypothesis that the induction of both innate and viral-specific immune responses might be beneficial during active SARS-CoV-2 antigenic exposure and provides
further rationale for combining BCG-based vaccines with other approved vaccines. Recent preclinical evidence corroborated this notion: BCG:CoVac, a formulation combining BCG with a stabilized form of the spike (S) protein resulted in the stimulation of SARS-CoV-2-specific antibody and T-cell responses in mice at the levels equivalent to or exceeding responses elicited by current clinical-stage vaccines in the murine models (37). Further demonstrating complex interplay between innate and adaptive immunity, a randomized clinical trial of topical BCG in children having common warts caused by the human papillomavirus, showed 65% complete responses, with no response detected in the control group (38). In conclusion, these preliminary studies suggest that BCG vaccination could enhance vaccine-induced immunity against SARS-CoV-2.

**NOVEL BCG-BASED APPROACHES**

Unlike other vaccination platforms, the robust safety and immunogenicity profile of BCG has rendered it an attractive vector for vaccine development against many viral or bacterial diseases. Antigens expressed by recombinant BCG (rBCG) strains can elicit long-lasting humoral and cellular immunity, including CD4+ and CD8+ T cell responses, to the foreign antigens in animals or humans. Recombinant BCG technology has been studied in the context of vaccination against HIV (39, 40), HCV (41), hMPV (42), RSV (43), rotavirus (44), *Bordetella pertussis* (45), Lyme disease (46), malaria (47), and measles (48). Furthermore, when administered in early life, BCG vaccination can act as an adjuvant enhancing antibody responses to recombinant hepatitis B surface antigen (rHBsAg) both in mice and in human infants (49, 50).

One of the promising novel approaches is the development of live rBCG engineered to express SARS-CoV-2 antigens to enhance innate and adaptive immune responses and induce sustained antigen presentation. The overall design strategy is based on the hypothesized ability of rBCG-SARS-CoV-2 bacteria to deliver antigens to lymphoid organs, prime a multifunctional T-cell response and induce long-term systemic and pulmonary protective T-cell immunity. Overall, T-cell responses against the S, N, and M antigens have been reported to be the most dominant and long lasting (51). Accordingly, a priority should be given to the viral antigens or epitopes that are identical to the SARS-CoV-1 and do not include any mutations in the available SARS-CoV-2 sequences, specifically mapped to the S, N, or M structural proteins. Several groups around the world are currently pursuing the construction of such next-generation BCG-based vaccines (52, 53). An earlier-generation genetically modified rBCG-based vaccine, VPM1002 has already entered clinical trials (NCT04387409, NCT04439045) for reducing SARS-CoV-2 infection rate and COVID-19 severity. VPM1002 expresses listeriolysin O (LLO) derived from *Listeria monocytogenes* and deleted Urease C (ureC) gene and has been demonstrated to be safer and more immunogenic in preclinical studies (54).

A different approach by Carlos Martin and colleagues generated a live attenuated *M. tuberculosis* vaccine (MTBVAC) that confers protection against pneumonia through the induction of epigenetic and metabolic reprogramming of monocytes associated with trained immunity (55). This represents a unique approach that does not use a cow-derived attenuated M. bovis strain but a human-derived *M. tuberculosis* with deletion of phoP and faD25 genes, which is currently under clinical trial.

**DISCUSSION**

Bacillus Calmette-Guérin (BCG) vaccination has been effective for nearly a century against Tuberculosis (TB), but it has also been described to reduce childhood mortality in a non-specific manner (6, 56, 57). The BCG is a live-attenuated vaccine that represents the most widely used vaccine in the world, with more than 4 billion people vaccinated with BCG worldwide and another 100 million newborn children vaccinated with BCG each year, providing over 50% protection against lung respiratory diseases and over 80% protection against disseminated TB (8). The mechanisms by which BCG induces a cross-protection against other diseases and specifically respiratory tract infections, has been established during the last decade and suggests a critical role of the innate immune system (58). The concept of trained immunity brings new insights into the immunological memory concept and described that cells from the innate immune system, such as macrophages, are able to recall a first encounter with a pathogen and produce an enhanced response toward a second assault. As a result, several studies on the cross-protective effects of the BCG vaccines have demonstrated that the positive effects on susceptibility to viral respiratory infections is associated with induction of trained immunity.

Introduction of BCG in developed countries is associated with reduction of mortality that cannot be explained by a specific disease protection. A recent case cohort study by Aaby et al. reported a better survival rates in Denmark associated to smallpox and tuberculosis vaccination during childhood (59). The study described that individuals who were vaccinated at a young age with both BCG and Vaccinia had a lower mortality rate (adjusted hazard ratio of 0.54) compared to non-vaccinated individuals (adjusted hazard ratio of 1). Interestingly, the study demonstrated the protective role of BCG to lower natural causes of death (adjusted hazard ratio of 0.57) after more than 30 years since BCG vaccination, suggesting that BCG may contribute to lower the mortality long-term. Together with other studies, these conclusions led to further investigations aimed at determining the durability of the BCG vaccine. A similar study suggested that the BCG vaccine remains effective after several decades following vaccination. A retrospective population-based cohort study carried out in Norway revealed that the BCG vaccine effectiveness against pulmonary tuberculosis remains at 40% after 30–40 years (60). Since BCG-derived immunity persist beyond 15 years after vaccination, it is plausible to hypothesize that BCG-induced non-specific protection could also last for decades. Consistent with this view, Mayda and Ishan Gursel hypothesized that countries with continuing BCG immunization programs better contain the spread of SARS-CoV-2 and reported statistical differences between five European countries after 11–22 years since last BCG vaccination and 8 European countries...
| Trial ID         | Source                  | Acronym | Status                | Interventions                          | Type                      | Design                      | Phase | Primary | Enrollment | Age  | Locations                          | Strain         |
|------------------|-------------------------|---------|-----------------------|----------------------------------------|---------------------------|------------------------------|-------|---------|------------|------|------------------------|----------------|
| NCT04327206      | ClinicalTrials.gov      | BRACE   | Recruiting            | BCG vaccine vs. 0.9%NaCl               | Interventional           | Randomized                  | 3     | Prevention | 10,078     | ≥ 18 years | Australia             | Danish strain 1331 |
| NCT04369794      | ClinicalTrials.gov      | BATTLE  | Recruiting            | BCG vaccine vs. placebo                | Interventional           | Randomized                  | 4     | Treatment | 1,000      | ≥ 18 years | Brazil                | N/A             |
| NCT04659941      | ClinicalTrials.gov      | ProBCG  | Recruiting            | BCG vaccine                            | Interventional           | Randomized                  | 2     | Prevention | 1,000      | ≥ 18 years | Brazil                | N/A             |
| RBR-4ktg/U1111-1256–3892 | REBEC  | Recruiting            | BCG vs. placebo        | Interventional                         | Randomized               | 2                              | Prevention | 800      | 18–65 years | 361–1          | Brazil                | Moscow strain 361–1 |
| NCT04390045      | ClinicalTrials.gov      | COBRA   | Recruiting            | VPM1002 vs. placebo                    | Interventional           | Randomized                  | 3     | Prevention | 3,626      | ≥ 18 years | Canada                | VPM1002         |
| NCT0461858       | ClinicalTrials.gov      | EDCTP   | Recruiting            | BCG-Denmark vs. saline                 | Interventional           | Randomized                  | 4     | Prevention | 1,050      | ≥ 18 years | Cape Verde, Guinea-Bissau, Mozambique | Danish strain 1331 |
| NCT04373291      | ClinicalTrials.gov      | Recruiting | BCG-Denmark vs. saline | Interventional                         | Randomized               | 3                              | Prevention | 1,500    | 18–100 years | 12–80 years | Denmark               | Danish strain 1331 |
| NCT04542330      | ClinicalTrials.gov      | Recruiting | BCG-Denmark vs. saline | Interventional                         | Randomized               | 3                              | Prevention | 1,900    | 65–110 years | N/A            | Denmark               | BCG-1331, AJ Vaccines |
| NCT04347676      | ClinicalTrials.gov      | Recruiting | Diagnostic Test: Tuberculin test | Observational Case-Control | 100              | Prevention | 100    | 12–80 years | N/A            | Egypt                 | N/A            |
| NCT04350931      | ClinicalTrials.gov      | Recruiting | Not yet recruiting   | BCG vaccine vs. placebo                | Interventional           | Randomized                  | 3     | Prevention | 900        | ≥ 18 years | Egypt                 | Danish strain 1331 |
| NCT04384549      | ClinicalTrials.gov      | COVID-BCG | Recruiting            | BCG vaccine vs. placebo                | Interventional           | Randomized                  | 3     | Prevention | 1,120      | ≥ 18 years | France                | N/A, AJ Vaccine |
| NCT04387409      | ClinicalTrials.gov      | Recruiting | Active, not recruiting | VPM1002 vs. placebo                   | Interventional           | Randomized                  | 3     | Prevention | 59         | ≥ 18 years | Germany               | VPM1002         |
| NCT0435379       | ClinicalTrials.gov      | Recruiting | Recruiting            | VPM1002 vs. placebo                    | Interventional           | Randomized                  | 3     | Prevention | 2,038      | ≥ 60 years | Germany               | VPM1002         |
| NCT04414267      | ClinicalTrials.gov      | ACTIVATE II | Recruiting          | BCG vaccine vs. placebo                | Interventional           | Randomized                  | 4     | Prevention | 900        | ≥ 50 years | Greece                | Moscow strain 361–1 |
| EUCTR2020-001783-28-HU | BACH   | Authorized          | BCG vs. placebo       | Interventional                         | Randomized               | 3                              | Prevention | 1,000    | 18–65 years | N/A            | Hungary               | Danish strain 1331, SSI, Denmark |
| NCT04475302      | ClinicalTrials.gov      | Recruiting | Recruiting            | BCG vaccine (Freeze-dried)             | Interventional           | Non-Randomized               | 3     | Prevention | 2,175      | 60–80 years | India                 | N/A, Serum Institute of India |
| CTRI/2020/06/025854 | CTRI       | Recruiting       | BCG vaccine           | Interventional                         | Non-Randomized           | N/A                          | Prevention | 1,450    | 60–95 years | India               | BCG-Serum Institute of India |
| CTRI/2020/04/024833 | CTRI       | Recruiting       | BCG vs. placebo       | Interventional                         | Randomized               | N/A                          | Prevention | 1,826    | 18–65 years | India               | BCG-Denmark, Green Signal |
| Trial ID                        | Source                | Acronym       | Status          | Interventions                                                                 | Type            | Design     | Phase | Primary | Enrollment | Age                  | Locations | Strain                                      |
|--------------------------------|-----------------------|---------------|-----------------|-----------------------------------------------------------------------------|-----------------|------------|-------|---------|------------|---------------------|-----------|---------------------------------------------|
| CTRI/2020/05/025013            | CTRI                  |               | Not Recruiting  | BCG plus STANDARD of CARE as suggested by DCGI vs. SALINE plus STANDARD of CARE as suggested by DCGI | Interventional  | Non-randomized | 2     | Treatment | 60         | 20–50 years          | India     | Tubervac (Serum Institute of India)         |
| CTRI/2020/09/027684            | CTRI                  |               | Recruiting      | BCG vaccine vs. BCG re-vaccination                                          | Interventional  | Randomized  | N/A   | Prevention | 400        | 18–50 years          | India     | N/A                                         |
| CTRI/2020/04/024749            | CTRI                  |               | Not Recruiting  | VPM1002 vs. placebo 0.9% saline                                            | Interventional  | Randomized  | 3     | Prevention | 5,946      | 18–99 years          | India     | VPM1002                                    |
| CTRI/2020/07/026668            | CTRI                  |               | Not Recruiting  | BCG vs. placebo                                                             | Interventional  | Randomized  | 3     | Prevention | 800        | 18–60 years          | India     | N/A                                         |
| IRCT20200411-047019N1          | IRCT                  |               | Recruiting      | BCG vs. placebo                                                             | Interventional  | Randomized  | 3     | Prevention | 500        | ≥18 years            | Iran      | N/A                                         |
| NCT0461379 ClinicalTrials.gov  |                       | BCG-CORONA    | Active, not recruiting | BCG vaccine vs. placebo                                                     | Interventional  | Randomized  | 3     | Prevention | 908        | ≥18 years            | Mexico    | Tokio 172                                   |
| NCT04328441 ClinicalTrials.gov | ClinicalTrials.gov    | BCG-CORONA    | Active, not recruiting | BCG vaccine vs. placebo                                                     | Interventional  | Randomized  | 3     | Prevention | 1,500      | ≥18 years            | Netherlands | Danish strain 1331                           |
| NCT04417335 ClinicalTrials.gov | ClinicalTrials.gov    | BCG-CORONA    | Active, not recruiting | BCG vaccine vs. placebo                                                     | Interventional  | Randomized  | 4     | Prevention | 2,014      | ≥60 years            | Netherlands | Danish strain 1331                           |
| NCT04537663 ClinicalTrials.gov | ClinicalTrials.gov    | BCG-CORONA    | Recruiting      | BCG vaccine vs. placebo                                                     | Interventional  | Randomized  | 4     | Prevention | 5,200      | ≥60 years            | Netherlands | Danish strain 1331                           |
| EUCTR2020-002456-21-NL         | EU Clinical Trials Register | BCG-CORONA    | Not Recruiting  | BCG, BCG plus MMR, BCG plus alendronic acid, alendronic acid, placebo      | Interventional  | Randomized  | 4     | Prevention | 100        | 18–64 years          | Netherlands | N/A, AJ VACCINES                           |
| NL8547                         | Netherlands Trial Register | BCG-CORONA    | Recruiting      | BCG vs. placebo                                                             | Interventional  | Randomized  | N/A   | Prevention | 1,600      | ≥60 years            | Netherlands | N/A                                         |
| NCT04648800 ClinicalTrials.gov |                       |               | Recruiting      | BCG-10 vaccine vs. 0.9% saline                                              | Interventional  | Randomized  | 3     | Prevention | 1,000      | ≥25 years            | Poland     | Moreau                                      |
| NCT04379336 ClinicalTrials.gov |                       |               | Recruiting      | BCG vaccine vs. placebo                                                      | Interventional  | Randomized  | 3     | Prevention | 500        | ≥18 years            | South Africa | Danish strain 1331                          |
| NCT04348370 ClinicalTrials.gov |                       |               | Recruiting      | BCG vaccine vs. placebo                                                      | Interventional  | Randomized  | 4     | Prevention | 1,800      | 18–75 years          | United States | Tice BCG                                   |
| NCT04534803 ClinicalTrials.gov |                       |               | Not yet recruiting | BCG vaccine vs. placebo                                                      | Interventional  | Randomized  | 3     | Prevention | 2,100      | ≥70 years            | United States | Tokio 172                                  |
| NCT04632537 ClinicalTrials.gov |                       |               | Recruiting      | Tice BCG vs. saline                                                          | Interventional  | Randomized  | 3     | Prevention | 550        | 18–64 years          | United States | Tice BCG                                   |
after 30–45 years. These studies also speculate that BCG re-vaccination represents a valid approach to increase the vaccine effectiveness (31). On the other hand, other studies demonstrated the absence between a decrease of positive SARS-CoV-2 test results and BCG-vaccinated adults aged 39–41 years vs. non-vaccinated aged 35–37 years, suggesting that the BCG vaccine does not interfere with infection in young adults (61). A recent retrospective observational study carried out in healthcare workers in Los Angeles demonstrated that history of BCG vaccination was associated with an altered seroprevalence and infection with SARS-CoV-2. Specifically, the study indicated that BCG vaccinated healthcare workers were less likely to suffer COVID-19 related symptoms (fatigue, dry cough, and muscle aches), were associated to have a reduced rate of testing positive either with a COVID-19 diagnosis by a medical doctor or a SARS-CoV-2 RT-PCR test and had a significantly lower positive serology against SARS-CoV-2 (IgG) (62). Overall, these finding suggest that BCG vaccination may mitigate sickness associated with COVID-19 infection and ongoing clinical trials are aimed at specifically address this question.

Since the BCG vaccine has proven protection against viral respiratory infections, several laboratories are exploring the possibility that the BCG vaccine could be used alone or synergistically to reduce COVID-19 disease severity. Nowadays, around 20 controlled randomized clinical trials ongoing in the Netherlands, Australia, Germany, Greece, the United States, Egypt, Colombia, Mexico, Brazil, South Africa, Denmark, and France (Table 1) to evaluate whether the BCG vaccine decreases the incidence and the severity of COVID-19. The importance of establishing age groups that might be protected against SARS-CoV2 infection by BCG-vaccination is evident, as well as the timing of the vaccine before potential exposure to the virus, as this may determine whether the BCG-vaccine is effective. This represents a critical step to assess the potential of BCG-vaccination to protect the elderly against SARS-CoV-2 and other respiratory infectious agents. However, additional from the above ongoing RCTs are needed to specifically demonstrate the effects of BCG vaccination in the morbidity and mortality of COVID-19 in different scenarios. For example, BCG could be administered in clinics via multiple routes, which potentially include direct mucosal delivery. Whereas current trials with BCG for COVID-19 all rely on the intradermal injections, the oral BCG has been used in Brazil for vaccination against TB until the 1970s. Mimicking the natural mycobacterial infection route by mucosal vaccination with BCG has been known to generate superior protection against TB in animal models. Oral or intranasal BCG vaccination has been shown to induce greater mucosal immune responses and better protection against pulmonary TB compared with subcutaneous vaccination in animals via potent induction of lung parenchyma- and airway-resident memory T cells populations (63, 64). In this respect, immunization with recombinant BCG-N-hRSV protects from hRSV virus associated-lung damage, decreases the infiltration of inflammatory immune cells to the lungs and reduces the virus in the lung tissues when mice were infected with hRSV (65, 66). Based on this evidence, it is possible that mucosal (oral or aerosolized) administration of BCG that engages trained immunity locally may lead to more effective innate immune responses in lungs of COVID-19 patients.

We conclude that, in addition to protection from COVID-19 disease, SARS-CoV-2 viral production and death, BCG clinical trials that evaluate (i) alternative routes of administration, (ii) its potential use as adjuvant, and (iii) its potential to prevent concurrent respiratory diseases will be very informative. While some vaccines rely on additional adjuvants in their formulation, live BCG has strong "self-adjuvant" properties that stimulate multiple innate immune sensors or PRRs, including TLR2, TLR4, TLR8, C-type lectin receptors Dectin-1, and Mincl that enhance vaccine induced immunity (67). While the main line of research and therapeutic approaches are focused on the adaptive immune response against SARS-CoV-2, we should not forget the primordial role of the innate immune response against infections. The possibility to stimulate the innate immune system represents a synergistic methodology that should be further explored to shield individuals against SARS-CoV-2 and unknown invading pathogens. Together with BCG, other live attenuated vaccines are currently used to protect against specific infections such as vaccinia (MVA), YFV, measles, mumps, rubella, rotavirus, or attenuated influenza vaccines. It will be therefore interesting to explore the effects of these vaccines that trigger the innate immune response to enhance the basal defenses against coming pathogens, with open questions about their specificity, level of protection, and durability (68).

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

The authors’ work is supported by National Institutes of Health grants R01 AI139623AI and Ministerio de Ciencia e Innovación PID2019-110015RB-100 (JO); PID2019-105761RB-100 (EN-V). MG-P is funded from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 860003.

REFERENCES

1. Vitale M. Zoonotic tuberculosis: a complex issue of the Mycobacterium tuberculosis complex. Lancet Microbe. (2020) 1:e45–e6. doi: 10.1016/S2666-5247(20)30032-X
2. Luca S, Mihaescu T. History of BCG vaccine. Maedica. (2013) 8:53–8. Available online at: https://www.maedica.ro/jcm-vol-8-11-nr-1-2013/
3. Vaccination préventive de la tuberculose de l’homme et des animaux par le B C G. Rapports et documents provenant des divers pays (la France exceptée) transmis à l’Institut Pasteur en (1932). J Am Med Assoc. (1932) 99:940–1. doi: 10.1001/jama.1932.02740630060039
4. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ. (2000) 321:1435–8. doi: 10.1136/bmj.321.7274.1435
5. Garly ML, Martins CL, Balé C, Balde MA, Hedegaard KL, Gustafson P, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine. (2003) 21:2782–90. doi: 10.1016/S0264-410X(03)00181-6

6. Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine. (2005) 23:1251–7. doi: 10.1016/j.vaccine.2004.09.006

7. Ohrui T, Nakayama K, Fukushima T, Chiba H, Sasaki H. [Prevention of elderly virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Ann. N. Engl. J. Med. (2011) 43:185–90. Retrieved from https://pubmed.ncbi.nlm.nih.gov/21979284/

8. Nemes E, Geldenhuys H, Ruzot V, Rutkowski KT, Ratenge F, Bilek N, et al. Prevention of M. tuberculosis infection with H4IC31 vaccine or BCG revaccination. N. Engl. J. Med. (2018) 379:139–48. doi: 10.1056/NEJMoa1714021

9. Moorlag SJCF, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccination on both heterologous Th1/Th17 differentiation and trained innate immunity. J Innate Immun. (2017) 9:241–59. doi: 10.1159/000489801

10. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy of Bacillus Calmette-Guerin-vaccination and COVID-19 (2020). Available online at: https://www.who.int/publications/i/item/bacille-calmette-guerin%20-%28bcg%29-vaccination-and-covid-19

11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. (2020) 383:2603–15. doi: 10.1056/NEJMa2034577

12. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. (2020) 181:1016–35.e19. doi: 10.1016/j.cell.2020.04.035

13. Hamiel U, Kozer E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. JAMA. (2020) 323:2340–1. doi: 10.1001/jama.2020.8189

14. O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev. Immunol. (2020) 20:335–7. doi: 10.1038/s41577-020-0337-y

15. ﻿Nuovo G, Tili E, Suster D, Matys E, Hupp L, Magro C. Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine. Ann. Diagn. Pathol. (2020) 48:151600. doi: 10.1016/j.anndiagpath.2020.151600

16. ﻿Kleinijenhuis J, Quintijn J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, et al. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin. Immunol. (2014) 155:213–9. doi: 10.1016/j.clim.2014.10.005

17. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl Acad Sci U S A. (2007) 104:5956–61. doi: 10.1073/pnas.0700869104

18. ﻿Abdallah AM, Hill-Cawthorne GA, Otto TD, Coll F, Guerra-Assunção JA, Gao G, et al. Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations. Sci. Rep. (2015) 5:15443. doi: 10.1038/srep15443

19. ﻿Zhang L, Ru HW, Chen FZ, Jin CY, Sun RF, Fan XY, et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol. Ther. (2016) 24:398–405. doi: 10.1038/mt.2015.216

20. ﻿Tran V, Ahn SK, Ng M, Li M, Liu J. Loss of lipid virulence factors reduces the efficacy of the BCG vaccine. Sci. Rep. (2016) 6:29076. doi: 10.1038/srep29076

21. Secretariat SWGooVaW. Report on BCG Vaccine Use for Protection against Mycobacterial Infections Including Tuberculosis, Leprosy, and Other Nontuberculous Mycobacteria (NTM) Infections (2017).

22. Gursel M, Gursel I. Is global BCG vaccine-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy. (2020) 75:1815–9. doi: 10.1111/all.14345

23. Ozedmir C, Kucuksezer UC, Tamay ZU. Is BCG vaccination affecting the spread and severity of COVID-19? Allergy. (2020) 75:1824–7. doi: 10.1111/all.14344

24. Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. (2020) 395:1545–6. doi: 10.1016/S0140-6736(20)31025-4

25. Hamid U, Koeber E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. JAMA. (2020) 323:2340–1. doi: 10.1001/jama.2020.8189

26. ﻿Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc. Natl Acad Sci U S A. (2020) 117:17720–6. doi: 10.1073/pnas.2008410117

27. Patella V, Delfino G, Bruzzi D, Giuliano A, Sanduzzi A. The bacillus Calmette-Guerin vaccination allows the innate immune system to provide protection from severe COVID-19 infection. Proc. Natl Acad Sci U S A. (2020) 117:25205–6. doi: 10.1073/pnas.200514117

28. Conououpas C, Stella AO, Bhattacharya ND, Grey A, Patel K, Ferguson AL, et al. A single dose, BCG-adjuvanted SARS-CoV-2 vaccine induces Th1-polarized immunity and high titre-neutralizing antibodies in mice. bioRxiv. [pre-print]. (2020). doi: 10.1101/2020.12.10.419044

29. Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable BCG Calmette-Guerin. Pediatr. Dermatol. (2013) 30:60–3. doi: 10.1111/j.1525-1470.2012.01848.x

30. ﻿Küpeläinen A, Sautili H, Guitart N, Moyo N, Wee EG, Ravi K, et al. Priming with recombinant BCG expressing novel HIV-1 conserved mosaic immunogens and boosting with recombinant ChAdOx1 is safe, stable, and elicits HIV-1-specific T-cell responses in BALB/c mice. Front. Immunol. (2019) 10:923. doi: 10.3389/fimmu.2019.00923

31. Kim BJ, Kim BR, Kook YH. Development of a live recombinant BCG expressing human immunodeficiency virus type 1 (HIV-1) gag using a pMyong2 vector system: potential use as a novel HIV-1 vaccine. Front. Immunol. (2019) 5:2305–6. doi: 10.3389/fimmu.2019.00643

32. Uno-Furuta S, Matsuo K, Tamaki S, Takamura S, Kamei A, Kuromatsu I, et al. A single dose, BCG-adjuvanted SARS-CoV-2 vaccine induces Th1-polarized immunity and high titre-neutralizing antibodies in mice. bioRxiv. [pre-print]. (2020). doi: 10.1101.2020.12.10.419044

33. ﻿Sautili H, Guitart N, Moyo N, Wee EG, Ravi K, et al. Immunization with recombinant Calmette-Guerin vaccination allows the innate immune system to provide protection from severe COVID-19 infection. Proc. Natl Acad Sci U S A. (2020) 117:25205–6. doi: 10.1073/pnas.200514117

34. Palavecino CE, Céspedes PF, Gómez RS, Kalergis AM, Bueno SM. (2020). doi: 10.1101/2020.12.10.419044
protective Th1 immunity against the human metapneumovirus. *J Immunol.* (2014) 192:214–23. doi: 10.4049/jimmunol.1300118

43. Rey-Jurado E, Soto J, Galvés N, Kalgari AM. A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus. *Hum Vaccin Immunother.* (2017) 13:2092–7. doi: 10.1080/21645515.2017.1334026

44. Dennehly M, Bourn W, Steele D, Williamson AL. Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine. *Vaccine.* (2007) 25:3646–57. doi: 10.1016/j.vaccine.2007.01.017

45. Andrade PM, Chade DC, Borra RC, Nascimento IP, Villanova FE, Leite LC, et al. The therapeutic potential of recombinant BCG expressing the antigen S1P in the intravesical treatment of bladder cancer. *Urol Oncol.* (2010) 28:520–5. doi: 10.1016/j.urolonc.2008.12.017

46. Stover CK, Bansi GP, Hanson MS, Burlein JE, Palaszynski SR, Young JF, et al. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. *J Exp Med.* (1993) 178:197–209. doi: 10.1084/jem.178.1.197

47. Matsumoto S, Yukiike T, Kanbara H, Yamada T. Recombinant *Mycobacterium bovis* bacillus Calmette-Guerin secreting merozoite surface protein 1 (MSPI) induces protection against rodent malaria parasite infection depending on MSPI-stimulated interferon gamma and parasite-specific antibodies. *J Exp Med.* (1998) 188:845–54. doi: 10.1084/jem.188.5.845

48. Zhu YD, Fennelly G, Miller C, Tarara R, Saxe I, Bloom B, et al. Recombinant bacille Calmette-Guerin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. *J Infect Dis.* (1997) 176:1445–53. doi: 10.1086/514140

49. Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, et al. Evaluation of recombinant bacille Calmette-Guerin vaccine against experimental lethal pneumonia. *PLoS Pathog.* (2020) 16:e1008404. doi: 10.1371/journal.ppat.1008404

50. Kjærgaard J, Birk NM, Nissen TN, Thostesen LM, Pihl GT, Benn CS, et al. Non-specific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial. *Pediatr Res.* (2016) 80:681–5. doi: 10.1038/pr.2016.142

51. Shann F. The non-specific effects of vaccines. *Arch Dis Child.* (2010) 95:662–7. doi: 10.1136/adc.2009.157537

52. Kleininnjenhuis J, Quintin J, Preijers F, Joosten LA, Iffim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc Natl Acad Sci U S A.* (2012) 109:17537–42. doi: 10.1073/pnas.1202870109

53. Rieckmann A, Villumsen M, Sorup S, Haugaard LK, Ravn H, Roth A, et al. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010. *Int J Epidemiol.* (2017) 46:695–705. doi: 10.1093/ije/dyw120

54. Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. *Lancet Infect Dis.* (2016) 16:219–26. doi: 10.1016/S1473-3099(15)00400-4

55. Shelby MD. Results of NTP-sponsored mouse cytogenetic studies on 1,3-bactadiene, isoprene, and chloroprene. *Environ Health Perspect.* (1990) 86:761–3. doi: 10.1289/ehp.908671

56. Rivas MN, Ebinger JE, Wu M, Sun N, Braun J, Sobhani K, et al. BCG vaccination history associates with decreased SARS-CoV-2 seropositivity across a diverse cohort of health care workers. *J Clin Invest.* (2021) 131:e145157. doi: 10.1172/JCI145157

57. Tanner R, Villarreal-Ramos B, Vordermeier HM, McShane H. The humoral immune response to BCG vaccination. *Front Immunol.* (2019) 10:1317. doi: 10.3389/fimmu.2019.01317

58. Perdomo C, Zedler U, Kühl AA, Lozza L, Saikali P, Sander LE, et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. *mBio.* (2016) 7:e01686-16. doi: 10.1128/mBio.01686-16

59. Cespedes PF, Rey-Jurado E, Espinoza JA, Rivera CA, Canedo-Marroquin G, Bueno SM, et al. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice. *Vaccine.* (2017) 35:757–66. doi: 10.1016/j.vaccine.2016.12.048

60. Cautivo KM, Bueno SM, Cortes CM, Wozniak A, Riedel CA, Kalgari AM. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacille Calmette-Guerin promotes virus clearance and protects from infection. *J Immunol.* (2010) 185:7633–45. doi: 10.4049/jimmunol.0903452

61. Rius-Rocabert S, Linares Pinel F, Pozuelo MJ, García A, Nistal-Villan E. Oncolytic bacteria: past, present and future. *FEBS Microbiol Lett.* (2019) 366:fzn136. doi: 10.1093/femsle/fzn136

62. Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. *Front Immunol.* (2018) 9:2936. doi: 10.3389/fimmu.2018.02936

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Gonzalez-Perez, Sanchez-Tarjuelo, Sher, Nistal-Villan and Ochoano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.